About Oncimmune
Oncimmune is a company based in Nottingham (United Kingdom) founded in 2006 by Geoffrey Hamilton Fairley was acquired by Freenome in May 2023. It operates as a Professional Services and Data-as-a-Service. Oncimmune has completed 1 acquisition, including Protagen. Oncimmune offers products and services including ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science. Oncimmune operates in a competitive market with competitors including Biodesix, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others.
- Headquarter Nottingham, United Kingdom
- Founders Geoffrey Hamilton Fairley
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alden Scientific Holdings Incorporated
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2.87 M (USD), Post-IPO
Oct 21, 2024
-
Investors
Freenome Health
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Freenome
(May 22, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oncimmune
Oncimmune offers a comprehensive portfolio of products and services, including ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science.
Platform used for antibody biomarker discovery and analysis.
Services offered for customized biomarker panel development.
Analytics provided for biomarker data integration and insights.
Funding Insights of Oncimmune
Investors in Oncimmune
Oncimmune has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Freenome Health, HHS and UK Research and Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alternative financing is provided by IPF Partners for healthcare.
|
Locked | Locked | Locked | |
|
Research and innovation funding is managed for UK advancement.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Oncimmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oncimmune
Oncimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Protagen.
Investment portfolio details for Oncimmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Autoantibody biomarkers are utilized for autoimmune disease diagnostics.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Oncimmune
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Oncimmune
Detailed financials for Oncimmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncimmune Comparisons
Peer comparison for Oncimmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oncimmune
Oncimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biodesix, OncoCyte, Broncus, Riverain Tech and ONCOHOST, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer detection diagnostics assays are developed and offered.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive technologies for lung disease treatment are developed.
|
|
| Locked | Locked | Locked |
Software tools are developed for early lung disease detection.
|
|
| Locked | Locked | Locked |
AI-based proteomic analysis for oncology therapy planning is offered.
|
Detailed competitors of Oncimmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncimmune
Complete news archive for Oncimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncimmune
Oncimmune was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Oncimmune is headquartered in Nottingham, United Kingdom.
Geoffrey Hamilton Fairley is the current CEO of Oncimmune. They have also founded this company.
Oncimmune is engaged in the development of advanced antibody biomarker discovery platforms, primarily through its proprietary ImmunoINSIGHTS engine. The company operates in the healthcare and biotechnology sectors, offering solutions for precision medicine across areas such as immuno-oncology, autoimmune diseases, and infectious diseases. Services include targeted panels, arrays, and bioinformatics for data integration. With a vast antigen library and cutting-edge technology, Oncimmune collaborates with clients to provide insights into the immune system for improved diagnostics and treatments.
Oncimmune offers ImmunoINSIGHTS™, Targeted Panels & Arrays, and Bioinformatics & Data Science.
Oncimmune has made 1 acquisition, including Protagen.
Oncimmune has 5 investors. Key investors include Freenome Health, HHS, UK Research and Innovation, IPF Partners, and Genostics.